Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

2008
https://researcherprofiles.org/profile/1459766
18383069
Bar-Or A, Calabresi PA, Arnold D, Arnlod D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH